Clinical Trial

Tempus Small Cell Lung Cancer Observational Study (Sculptor)

Recruiting
View on ClinicalTrials.gov →
Summary
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.
Protocol Amendment History 1 change
notable Enrollment increased: 50 -> 200 participants 2026-04-03
Trial Details
NCT Number NCT05257551
Lead Sponsor Tempus AI
Collaborators: AstraZeneca
Conditions Small Cell Lung Cancer
Enrollment 200 participants
Start Date 2022-07-13
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-15